Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-07-2009 | Original Paper

Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer

Authors: Hendrik Andreas Wolff, Tobias Overbeck, Ralph M. Roedel, Robert M. Hermann, Markus K. A. Herrmann, Tereza Kertesz, Hilke Vorwerk, Andrea Hille, Christoph Matthias, Clemens F. Hess, Hans Christiansen

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2009

Abstract

Purpose

To evaluate toxicity of radiochemotherapy schedule using daily-low-dose-cisplatin in radiochemotherapy of locally-advanced head-and-neck-cancer (HNSCC).

Methods and patients

From October 2003 to October 2006, 50 patients with HNSCC (stage III/IVA/IVB) were treated. In 32 patients, surgery and adjuvant radiotherapy(64 Gy), in 18 patients definitive radiotherapy(70 Gy) was performed. Low-dose-cisplatin was applied concomitantly (6 mg/m²/every radiotherapy-day).

Results

Acute toxicity ≥grade 3 was observed in 22 patients (11 patients mucositis/dysphagia, 7 hematologic toxicity, 4 mucositis/dysphagia/hematologic toxicity). 90% of our patients received >80% of the planned cumulative chemotherapy dose, 94% the intended dose of radiotherapy. After median follow-up of 24.2 months, 3-year overall survival and loco-regional control rates were 67.1 and 78%. During follow-up, chronic toxicity ≥grade 3 (xerostomia, subcutaneous fibrosis, or lymphedema) was observed in nine patients.

Conclusion

We found chemoradiation with daily-low-dose-cisplatin to be feasible with advantage of low acute and chronic toxicity. Therefore, use of low-dose-cisplatin should be evaluated in future clinical trials.

Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98. doi:10.1200/JCO.2003.01.008 PubMedCrossRef

Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M, Lavertu P et al (2006) Ma Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 24:1064–1071. doi:10.1200/JCO.2005.01.5867 PubMedCrossRef

Bauchaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveitzer N et al (1996) Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 36(5):999–1004. doi:10.1016/S0360-3016(96)00430-0

Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH et al (2004) Postoperative Irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945–1952. doi:10.1056/NEJMoa032641 PubMedCrossRef

Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L (2001) Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 23:579–589. doi:10.1002/hed.1081 PubMedCrossRef

Budach W, Hehr T, Budach V, Belka C, Dietz K (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresectable locally advanced squamous cell carcinom of the head and neck. BMC Cancer 6:28. doi:10.1186/1471-2407-6-28 PubMedCrossRef

Castro G, Snitcovsky IML, Gebrim EM, Leitao GM, Nadalin W, Ferraz AR et al (2007) High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 264(12):1475–1482. doi:10.1007/s00405-007-0395-9 PubMedCrossRef

Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamos-cell carcinom of the head and neck. N Engl J Med 350(19):1937–1944. doi:10.1056/NEJMoa032646 PubMedCrossRef

Corvo R (2007) Evidence based radiation oncology in head and neck squamos cell carcinoma. Radiother Oncol 85(1):156–170. doi:10.1016/j.radonc.2007.04.002 PubMedCrossRef

El-Sayed S, Nelson N (1996) Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region A meta-analysis of prospective and randomized trials. J Clin Oncol 14:838–847PubMed

Geeta SN, Padmanabhan TK, Samuel J, Pavithran K, Lyer S, Kuriakose MA (2006) Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers. JCRT 2(3):100–1004PubMed

Hoebers FJ, Heemsbergen W, Balm AJ, van Zanten M, Schornagel JH, Rasch CR (2007) Concurrent chemoradiation with daily low dose cisplatin for advanced stage head and neck carcinoma. Radiother Oncol 85(1):42–47. doi:10.1016/j.radonc.2007.03.014 PubMedCrossRef

International Commission on Radiation Units and Measurements Prescribing, Recording and Reporting Photon Beam Therapy (1993) ICRU report No. 50. ICRU, Bethesda

Jeremic B, Milicic B (2008) Influence of low-dose cisplatin on the distant metastasis-free survival of patients with locally advanced nonmetastatic head and neck cancer treated with radiation therapy. Radiother Oncol 87(2):201–203. doi:10.1016/j.radonc.2007.12.023 PubMedCrossRef

Jeremic B, Milicic B, Dagovic A, Vaskovic Z, Tadic L (2004) Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of th head and neck. J Clin Oncol 22(17):3540–3548. doi:10.1200/JCO.2004.10.076 PubMedCrossRef

Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 58:457–481. doi:10.2307/2281868 CrossRef

Lau H, Brar S, Hao D, MacKinnon J, Yee D, Gluck S (2006) Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: analysis of survival and toxicity. Head Neck 28(3):189–196. doi:10.1002/hed.20324 PubMedCrossRef

Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355:949–955PubMed

Pradier O, Lederer K, Hille A, Weiss E, Christiansen H, Schmidberger H et al (2005) Concurrent low-dose cispaltin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the haemoglobin level as prognostic parameter. J Cancer Res Clin Oncol 131(4):261–269. doi:10.1007/s00432-004-0633-0 PubMedCrossRef

Rades D, Fehlauer F, Sheikh-Sarraf M, Kazic N, Basic H, Poorter R et al (2008) Toxicity of two cisplatin-based radiochemotherapy regimes for the treatment of patients with stage III/IV head and neck cancer. Head Neck 30(2):235–241. doi:10.1002/hed.20683 PubMedCrossRef

Rubin P, Constine LSIII, Fajardo LF, Phillips TL, Wassermann TH (1995) EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system. Radiother Oncol 35:9–10. doi:10.1016/0167-8140(95)97447-L PubMedCrossRef

Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houte P et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326(8):524–530PubMedCrossRef

Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Klautke G et al (2007) 6-year experience of concurrent radiochemotherapy with vinorelbine plus a platinum compound in multimorbis or aged patients with inoperable non-small cell lung cancer. Strahlenther Onkol 183(1):30–35. doi:10.1007/s00066-007-1593-5 PubMedCrossRef

Takiguchi Y, Urama R, Asaka-Amano Y, Kuroso K, Kasahara Y, Tanabe N et al (2005) Phase I study of cisplatin and irinotecan combined with concurrent hyperfractionated accelerated thoracic radiotherapy for locally advanced non-small cell lung carcinoma. Int J Clin Oncol 10(6):418–424. doi:10.1007/s10147-005-0525-6 PubMedCrossRef

Trotti A, Byhardt R, Stetz J, Gwede C, Com B, Fu K et al (2000) Common toxicity criteria: Version 2.0 an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13–47. doi:10.1016/S0360-3016(99)00559-3 PubMed

Welz H, Pöttgen C, Abu Jawad J et al (2007) Hyperfraktioniert-akzelerierte (HAF) vs. konventionell fraktionierte (CF) Strahlentherapie und simultane Chemotherapie (CTx) mit Mitomycin C und 5-FU bei lokal fortgeschrittenen Kopf-Hals-Karzinomen: Monoinstitutionale Ergebnisse an 299 Patienten. Strahlenther Onkol 2007:94–95

Zuur CL, Simis YJ, Verkaik RS, Schornagel JH, Balm AJ, Dreschler WA, Rasch CR (2008) Hearing loss due to concurrent daily low-dose cispaltin chemoradiation for locally advanced head and neck cancer. Radiother Oncol 89(1):38–43. doi:10.1016/j.radonc.2008.06.003 PubMedCrossRef

Title: Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer
Authors: Hendrik Andreas Wolff
Tobias Overbeck
Ralph M. Roedel
Robert M. Hermann
Markus K. A. Herrmann
Tereza Kertesz
Hilke Vorwerk
Andrea Hille
Christoph Matthias
Clemens F. Hess
Hans Christiansen
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 7/2009
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-008-0532-x

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer

Abstract

Purpose

Methods and patients

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods and patients

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2009

Down-regulation of plasma membranous Annexin A1 protein expression in premalignant and malignant lesions of the oral cavity: correlation with epithelial differentiation

Gastric cancer in the era of molecularly targeted agents: current drug development strategies

Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro

High-efficiency transfer and expression of AdCMV-p53 in human cervix adenocarcinoma cells induced by subclinical-dose carbon beam radiation

Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma

WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page